Kline Wendy
J Womens Hist. 2010;22(3):64-87. doi: 10.1353/jowh.2010.0588.
In January 1983, the FDA held one of only two scientific "Public Boards of Inquiry" in the history of the administration to determine whether to approve Depo-Provera for use as a contraceptive in the United States. At the hearing, ideas about gender and power played a central role in negotiations between scientists, doctors, patients, and women's health activists. The nature of the Depo-Provera Public Board of Inquiry lends itself to analysis of the interaction between and among these groups, each of which had a vested interest in the outcome of the FDA decision. The stories and strategies emerging from the actors involved in the Public Board of Inquiry reveal the enormous complexity of regulating reproduction in the late twentieth century.
1983年1月，美国食品药品监督管理局（FDA）举行了其管理历史上仅有的两次科学性“公众调查委员会”听证会之一，以决定是否批准醋酸甲羟孕酮注射液在美国作为一种避孕药使用。在听证会上，关于性别和权力的观点在科学家、医生、患者及女性健康活动家之间的谈判中发挥了核心作用。醋酸甲羟孕酮注射液公众调查委员会的性质有助于分析这些群体之间的相互作用，每个群体都对FDA的决定结果有着既得利益。参与公众调查委员会的各方所展现出的经历和策略揭示了20世纪后期生殖监管的巨大复杂性。
